Therapeutic response of unani medicine in the management of Daul Shalal al Ra'ash (Parkinson's disease)

Aim and Objectives: The study aimed to study the clinical evaluation of Parkinson’s
disease in detail and to assess the efficacy of selected Unani formulations in the
management of Parkinson’s disease.
Material and Methods: The study was designed as a randomized single-blind
comparative study with a sample size of 20. Ten patients in each groups A and B were
randomly selected. The formula A contains Waj, Aqarqarha, Tukhm e Konch, Asgand,
Kulanjan and the formula B contains Shehad and Usthukhudoos. The subjective
parameters like tremors, slow movements, impaired posture, rigid muscles, and facial
expressions were reduced significantly in both groups. Parkinson's disease
questionnaire – 39 (PDQ - 39) was used as an objective parameter.
Results: The overall response in group A revealed that 09 (90%) of patients had a
satisfactory response to their clinical symptoms and signs and 01 (10%) patient was
found in the categories of poor response whereas in group B 07 (70%) of patients had
a satisfactory response from their clinical symptoms and signs and 03 (30%) patients
were found in the categories of poor response. Moreover, both groups were found
safe without any adverse effects.
Conclusion: It can be concluded that the drugs of groups A and B produced a
significant effect in the treatment of Parkinson's disease. However, the biological
mechanisms through which the group A and B drugs reduce the clinical symptoms
and signs remain unclear and need to be validated with experimental and clinical
studies.